- MapLight shares sink on mixed phase 2 schizophrenia readoutMapLight Therapeutics’ stock plummeted more than 60% this morning after the neuro outfit dropped mixed results for a phase 2 trial of its experimental schizophrenia treatment.
- Legend Biotech CEO abruptly steps down without permanent replacementIn a sudden leadership shift, Legend Biotech announced that its CEO, Ying Huang, Ph.D., resigned on Friday, with no permanent replacement yet named.